Speciality Medicines Ltd
Speciality Medicines Ltd (SPML) last traded at ₹155, a market capitalisation of ₹136 crore, on a P/E of 10.5. Over the past 52 weeks the stock has ranged between ₹121 and ₹381. Speciality Medicines Ltd last reported results for the quarter ended Mar 2026, with sales of ₹45 crore and net profit of ₹8 crore. Figures are as of 25 Aug 2026 and are not real time.
Speciality Medicines Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Speciality Medicines Ltd quarterly results
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating profit | 4 | 8 |
| OPM % | 14% | 19% |
| Other income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| Profit before tax | 4 | 8 |
| Tax % | 36% | -1% |
| Net profit | 3 | 8 |
| EPS (₹) | 4.16 | 9.31 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Speciality Medicines Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 40 | 23 | 28 | 58 | 75 |
| Operating profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Net profit | 1 | 2 | 3 | 9 | 13 |
| EPS (₹) | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
TTM is the trailing twelve months to the most recent quarter.
Speciality Medicines Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 48%
- TTM
- 29%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 98%
- TTM
- 51%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 31%
- 3 Years
- 29%
- Last Year
- 26%
Speciality Medicines Ltd shareholding pattern
| % held | Mar 2026 |
|---|---|
| Promoters | 43.43% |
| FIIs | 0.24% |
| Public | 56.34% |
| No. of shareholders | 757 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Speciality Medicines Ltd corporate filings
- We hereby submit intimation regarding approval for Two new products in Ethiopia.Company Updatelow impact
Cruxal's analysis: Speciality Medicines Ltd has announced the receipt of regulatory approval for two new…
Read the full analysis - We hereby submit Press Release titled "Speciality Medicines Limited Secures Regulatory Approval for Two New Products in Ethiopia".Company Updatemedium impact
Cruxal's analysis: Speciality Medicines Limited has announced the receipt of regulatory approval for two new…
Read the full analysis - We hereby submit the Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding Appointment of Investor and Public Relations agency of the Company.Company Updatelow impact
Cruxal's analysis: Speciality Medicines Limited has announced the appointment of Capital Bridge Advisory…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Speciality Medicines Ltd
Cruxal reads every Speciality Medicines Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.